• Je něco špatně v tomto záznamu ?

Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report

DL. Murray, N. Puig, S. Kristinsson, SZ. Usmani, A. Dispenzieri, G. Bianchi, S. Kumar, WJ. Chng, R. Hajek, B. Paiva, A. Waage, SV. Rajkumar, B. Durie

. 2021 ; 11 (2) : 24. [pub] 20210201

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026102

Plasma cell disorders (PCDs) are identified in the clinical lab by detecting the monoclonal immunoglobulin (M-protein) which they produce. Traditionally, serum protein electrophoresis methods have been utilized to detect and isotype M-proteins. Increasing demands to detect low-level disease and new therapeutic monoclonal immunoglobulin treatments have stretched the electrophoretic methods to their analytical limits. Newer techniques based on mass spectrometry (MS) are emerging which have improved clinical and analytical performance. MS is gaining traction into clinical laboratories, and has replaced immunofixation electrophoresis (IFE) in routine practice at one institution. The International Myeloma Working Group (IMWG) Mass Spectrometry Committee reviewed the literature in order to summarize current data and to make recommendations regarding the role of mass spectrometric methods in diagnosing and monitoring patients with myeloma and related disorders. Current literature demonstrates that immune-enrichment of immunoglobulins coupled to intact light chain MALDI-TOF MS has clinical characteristics equivalent in performance to IFE with added benefits of detecting additional risk factors for PCDs, differentiating M-protein from therapeutic antibodies, and is a suitable replacement for IFE for diagnosing and monitoring multiple myeloma and related PCDs. In this paper we discuss the IMWG recommendations for the use of MS in PCDs.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026102
003      
CZ-PrNML
005      
20211026133216.0
007      
ta
008      
211013s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41408-021-00408-4 $2 doi
035    __
$a (PubMed)33563895
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Murray, David L $u Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. murray.david@mayo.edu
245    10
$a Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report / $c DL. Murray, N. Puig, S. Kristinsson, SZ. Usmani, A. Dispenzieri, G. Bianchi, S. Kumar, WJ. Chng, R. Hajek, B. Paiva, A. Waage, SV. Rajkumar, B. Durie
520    9_
$a Plasma cell disorders (PCDs) are identified in the clinical lab by detecting the monoclonal immunoglobulin (M-protein) which they produce. Traditionally, serum protein electrophoresis methods have been utilized to detect and isotype M-proteins. Increasing demands to detect low-level disease and new therapeutic monoclonal immunoglobulin treatments have stretched the electrophoretic methods to their analytical limits. Newer techniques based on mass spectrometry (MS) are emerging which have improved clinical and analytical performance. MS is gaining traction into clinical laboratories, and has replaced immunofixation electrophoresis (IFE) in routine practice at one institution. The International Myeloma Working Group (IMWG) Mass Spectrometry Committee reviewed the literature in order to summarize current data and to make recommendations regarding the role of mass spectrometric methods in diagnosing and monitoring patients with myeloma and related disorders. Current literature demonstrates that immune-enrichment of immunoglobulins coupled to intact light chain MALDI-TOF MS has clinical characteristics equivalent in performance to IFE with added benefits of detecting additional risk factors for PCDs, differentiating M-protein from therapeutic antibodies, and is a suitable replacement for IFE for diagnosing and monitoring multiple myeloma and related PCDs. In this paper we discuss the IMWG recommendations for the use of MS in PCDs.
650    _2
$a chromatografie kapalinová $x metody $7 D002853
650    _2
$a lidé $7 D006801
650    _2
$a lehké řetězce imunoglobulinů $x analýza $7 D007147
650    _2
$a mnohočetný myelom $x diagnóza $7 D009101
650    _2
$a myelomové proteiny $x analýza $7 D009194
650    _2
$a nádory plazmocelulární $x diagnóza $7 D054219
650    _2
$a spektrometrie hmotnostní - ionizace laserem za účasti matrice $x metody $7 D019032
655    _2
$a časopisecké články $7 D016428
700    1_
$a Puig, Noemi $u Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain
700    1_
$a Kristinsson, Sigurdur $u Faculty of Medicine, University of Iceland, Reykjavík, Iceland
700    1_
$a Usmani, Saad Z $u Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA
700    1_
$a Dispenzieri, Angela $u Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA $u Department of Hematology, Mayo Clinic, Rochester, MN, USA
700    1_
$a Bianchi, Giada $u Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
700    1_
$a Kumar, Shaji $u Department of Hematology, Mayo Clinic, Rochester, MN, USA
700    1_
$a Chng, Wee Joo $u Cancer Science Institute of Singapore, NUS, Singapore, Singapore $u Yong Loo Lin School of Medicine, NUS, Singapore, Singapore $u National University Cancer Institute, Singapore, Singapore
700    1_
$a Hajek, Roman $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Paiva, Bruno $u Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, Pamplona, Spain
700    1_
$a Waage, Anders $u Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway $u Department of Hematology, St. Olav's University Hospital, Trondheim, Norway
700    1_
$a Rajkumar, S Vincent $u Department of Hematology, Mayo Clinic, Rochester, MN, USA
700    1_
$a Durie, Brian $u Department of Hematology, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA, USA
773    0_
$w MED00187996 $t Blood cancer journal $x 2044-5385 $g Roč. 11, č. 2 (2021), s. 24
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33563895 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133222 $b ABA008
999    __
$a ok $b bmc $g 1714959 $s 1146609
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c 2 $d 24 $e 20210201 $i 2044-5385 $m Blood cancer journal $n Blood Cancer J $x MED00187996
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace